



(51) International Patent Classification:

A61K 51/10 (2006.01) *A61K 103/30* (2006.01)
A61P 35/00 (2006.01) *A61K 103/40* (2006.01)
A61K 103/20 (2006.01)

(21) International Application Number:

PCT/US2024/024155

(22) International Filing Date:

11 April 2024 (11.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/495,561 12 April 2023 (12.04.2023) US

(71) Applicants: **FUSION PHARMACEUTICALS INC.** [CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA). **ASTRAZENECA UK LIMITED** [GB/G-B]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).

(72) Inventor; and

(71) Applicant: **MONLISH, Darlene Anne** [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(72) Inventors: **CAICEDO, David Rodriguez**; 357 Raymond Road, Ancaster, Ontario L9K 0J8 (CA). **TURNBULL, William Leslie**; 1119 Cooke Boulevard, Apt B226, Burlington, Ontario L7T 0C7 (CA). **MAHAMMAD, Saleemulla**; 194 Whittington Dr., Ancaster, Ontario L9K 0H5 (CA). **VAN DYK, Dewald**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MUNIZ-MEDINA, Vanessa Marie**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SALLADA, Nathanael David**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CHEUNG, Sao Fong**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **HAN, Jeong Min**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **COMER, Frank Irvine**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WORREDE, Asurayya**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CHANG, Chien-ying**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New

York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: STEAP2-TARGETED COMPOUNDS AND USE THEREOF

(57) Abstract: The present disclosure provides compounds or pharmaceutically acceptable salts thereof, e.g., radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting STEAP2. The present disclosure also provides pharmaceutical compositions of such compounds or pharmaceutically acceptable salts thereof and methods of treatment for conditions, e.g., cancer, using such compounds, pharmaceutically acceptable salts thereof, or pharmaceutical compositions.

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

JACOBSTEIN, Jeffrey M.
Finnegan, Henderson, Farabow, Garrett & Dunner,
LLP
901 New York Avenue, NW
Washington, District of Columbia 20001-4413
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 04 September 2025 (04.09.2025)	
Applicant's or agent's file reference 16266-0002-00304	IMPORTANT NOTIFICATION
International application No. PCT/US2024/024155	International filing date (day/month/year) 11 April 2024 (11.04.2024)

1. The following indications appeared on record concerning:

☒ the applicant

☐ the inventor

☐ the agent

☐ the common representative

Name and Address FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario L8P 0A6 CANADA	State of Nationality CA	State of Residence CA
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person

☐ the name

☐ the address

☐ the nationality

☐ the residence

Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:

The person identified in Box 1 has been deleted from the records.

4. A copy of this notification has been sent to:

☒ the receiving Office

☒ the International Searching Authority

☐ the Authority(ies) specified for supplementary search

☐ the International Preliminary Examining Authority

☒ the designated Offices concerned

☐ the elected Offices concerned

☐ other:

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

JACOBSTEIN, Jeffrey M.
Finnegan, Henderson, Farabow, Garrett & Dunner,
LLP
901 New York Avenue, NW
Washington, District of Columbia 20001-4413
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 04 September 2025 (04.09.2025)			
Applicant's or agent's file reference 16266-0002-00304		IMPORTANT NOTIFICATION	
International application No. PCT/US2024/024155		International filing date (day/month/year) 11 April 2024 (11.04.2024)	
1. The following indications appeared on record concerning: ☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative			
Name and Address ASTRAZENECA UK LIMITED 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UNITED KINGDOM		State of Nationality GB	State of Residence GB
		Telephone No.	
		Facsimile No.	
		E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence			
Name and Address		State of Nationality	State of Residence
		Telephone No.	
		Facsimile No.	
		E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary: The person identified in Box 1 has been deleted from the records.			
4. A copy of this notification has been sent to: ☒ the receiving Office ☒ the International Searching Authority ☐ the Authority(ies) specified for supplementary search ☐ the International Preliminary Examining Authority ☒ the designated Offices concerned ☐ the elected Offices concerned ☐ other:			
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland		Authorized officer Tarbouriech Anne e-mail pct.team7@wipo.int Telephone No. +41 22 338 74 07	

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

JACOBSTEIN, Jeffrey M.
Finnegan, Henderson, Farabow, Garrett & Dunner,
LLP
901 New York Avenue, NW
Washington, District of Columbia 20001-4413
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 04 September 2025 (04.09.2025)	
Applicant's or agent's file reference 16266-0002-00304	IMPORTANT NOTIFICATION
International application No. PCT/US2024/024155	International filing date (day/month/year) 11 April 2024 (11.04.2024)

1. The following indications appeared on record concerning:

☒ the applicant☐ the inventor☐ the agent☐ the common representative

Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person☐ the name☐ the address☐ the nationality☐ the residence

Name and Address ASTRAZENECA AB SE-151 85 SÖDERTÄLJE SWEDEN	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:

The person identified in box 2 has been added as applicant for all designated States.

4. A copy of this notification has been sent to:

☒ the receiving Office
☒ the International Searching Authority
☐ the Authority(ies) specified for supplementary search

☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer
Tarbouriech Anne
e-mail pct.team7@wipo.int
Telephone No. +41 22 338 74 07